Table 3.
Antibody titers’ fold changes (FC) in previously infected and not previously infected cohorts of healthcare providers to monitor vaccine immune responses
| Analyzed cohorts | Mean FC | Min FC | Max FC | n (%) |
|---|---|---|---|---|
| PreViously infected subjects | ||||
| Post I / Pre | 1.8 | 0.0 | 3.8 | 35 (100.0%) |
| NotPreviously infected subjects | ||||
| Post I / Pre | 1.6 | 0.0 | 3.6 | 158 (100.0%) |
| Post II / Post I | 1.9 | 0.2 | 3.8 | 158 (100.0%) |
| Post II / Pre | 3.5 | 1.4 | 3.8 | 158 (100.0%) |
| Post II/Pre ≤ 3.1 | 2.6 | 1.4 | 3.1 | 30 (19.0%) |
| Post II/Pre 3.1< ≤ 3.3 | 3.2 | 3.1 | 3.3 | 12 (7.6%) |
| Post II/Pre 3.3< ≤ 3.8 | 3.7 | 3.3 | 3.8 | 116 (73.4%) |
| Post II/Pre = 3.8 | 3.8 | 72 (45.6%) | ||
Previously infected subjects = subjects infected to SARS-CoV-2
Not previously infected subjects = subjects not infected to SARS-CoV-2
Pre = anti - SARS-CoV-2 S titers before the first dose
Post I = anti - SARS-CoV-2 S titers 20 days after the first dose
Post II = anti - SARS-CoV-2 S titers 8 days after the second dose
mean FC = mean fold changes of anti - SARS-CoV-2 S mean geometric titers
n (%) = number of subjects (percentage)